Life-threatening haematochezia in a man with two gastrointestinal stromal tumours

2021 ◽  
Vol 14 (6) ◽  
pp. e243357
Author(s):  
Kinza Moin ◽  
Maitha Alneyadi ◽  
Sulaiman Shantour ◽  
David Olukolade Alao

A man in his 30s was brought by ambulance to the emergency department with a complaint of frank bright red rectal bleeding and dizziness. His blood pressure was 60/18 mm Hg. He was resuscitated with intravenous normal saline and an emergency blood transfusion. Following a negative emergency oesophagogastroduodenoscopy and colonoscopy, an angiographic CT of the abdomen revealed a large tumour in the ileum. After failing to stabilise him with multiple blood transfusions, he had an emergent laparotomy and surgical resection of the tumour, which was confirmed by histocytology as gastrointestinal stromal tumour (GIST). He made full recovery and was discharged home after 10 days. We discussed the challenges of managing significant lower gastrointestinal bleeding and reviewed the current management of GIST.

2003 ◽  
Vol 58 (2) ◽  
pp. 109-112 ◽  
Author(s):  
Magaly Gemio Teixeira ◽  
Marcos Vinicius Perini ◽  
Carlos Frederico S. Marques ◽  
Angelita Habr-Gama ◽  
Desidério Kiss ◽  
...  

The case of a patient with blue rubber bleb nevus syndrome who is infected by acquired immunodeficiency syndrome virus due to multiple blood transfusions is presented. This case shows that although it is a rare systemic disorder, blue rubber bleb nevus syndrome has to be considered in the differential diagnosis of chronic anemia or gastrointestinal bleeding. Patients should be investigated by endoscopy, which is the most reliable method for detecting these lesions. The patient underwent gastroscopy and enteroscopy via enterotomy with identification of all lesions. Minimal resection of the larger lesions and string-purse suture of the smaller ones involving all the layers of the intestine were performed. The string-purse suture of the lesions detected by enteroscopy proved to be an effective technique for handling these lesions, avoiding extensive intestinal resection and stopping the bleeding. Effective management of these patients demands aggressive treatment and should be initiated as soon as possible to avoid risks involved in blood transfusions, as occurred in this case.


2013 ◽  
Vol 66 (5) ◽  
pp. 438-440 ◽  
Author(s):  
Martin A Crook ◽  
Patrick L C Walker

There are many causes of raised serum ferritin concentrations including iron overload, inflammation and liver disease to name but a few examples. Cases of extreme hyperferritinaemia (serum ferritin concentration equal to or greater than 10 000 ug/l) are being reported in laboratories but the causes of this are unclear. We conducted an audit study to explore this further. Extreme hyperferritinaemia was rare with only 0.08% of ferritin requests displaying this. The main causes of extreme hyperferritinaemia included multiple blood transfusions, malignant disease, hepatic disease and suspected Still's disease.


PEDIATRICS ◽  
1992 ◽  
Vol 89 (4) ◽  
pp. 689-690
Author(s):  
ORNA FLIDEL ◽  
YIGAL BARAK ◽  
BEATRIZ LIFSCHITZ-MERCER ◽  
AZRIEL FRUMKIN ◽  
BENJAMIN M. MOGILNER

To the Editor.— Graft vs host disease (GVHD) in extremely low birth weight neonates following multiple blood transfusions is probably more frequent than is generally thought.1 Recently, such a case was described by Funkhouser et al.2 We wish to report our experience with an extremely low birth weight neonate with GVHD, presumably induced by blood transfusions. Immunotherapy with rat antilymphocyte monoclonal antibody(Campath 1G) failed to induce any clinical change. The patient was a boy,


PEDIATRICS ◽  
1961 ◽  
Vol 27 (3) ◽  
pp. 370-372
Author(s):  
Robert D. Gens

A patient who had received multiple blood transfusions and whose serum exhibited a leukocyte agglutinin is reported. This patient developed transfusion reactions characterized by chills, fever and lethargy when administered routine bloodbank and leukocyte-rich blood. No transfusion reaction was noted when the patient received leukocyte-poor blood.


2016 ◽  
Vol 45 (6) ◽  
pp. 270
Author(s):  
Rinawati Rohsiswatmo

Background Retinopathy of prematurity (ROP) is one of the ma-jor causes of infant blindness. There are several factors known asrisk factors for ROP. Recent studies show ROP as a disease ofmultifactorial origin.Objective To report the prevalence of ROP in Cipto MangunkusumoHospital, Jakarta and its relation to several risk factors.Methods A cross-sectional descriptive study was conducted fromDecember 2003-May 2005. All infants with birth weight 2500 gramsor less, or gestational age 37 weeks or less, were enrolled con-secutively and underwent the screening of ROP at 4 to 6 weeks ofchronological age or 31 to 33 weeks of postconceptional age.Result Of 73 infant who met the inclusion criteria, 26% (19 out of73 infant) had ROP in various degrees. About 36.8% (7 out of 19infants) were in stage III or more/threshold ROP. No ROP wasnoted in infants born >35 weeks of gestational age, and birth weight>2100 grams. No severe ROP was found in gestational age >34weeks and birth weight >1600 grams. None of full-term, small forgestational age infants experienced ROP. Birth weight, sepsis,apneu, asphyxia, multiple blood transfusions, and oxygen therapyfor more than 7 days were statistically significant with the develop-ment of ROP. However, using multivariate analysis, only asphyxia,multiple blood transfusions, and oxygen therapy for more than 7days were statistically significant with the development of ROP.Conclusion Screening of ROP should be performed in infantsborn 34 weeks of gestational age and/or birth weight <1600 grams.Infants with birth weight from 1600-<2100 grams need to bescreened only if supplemental oxygen is necessary or with clini-cally severe illness


2017 ◽  
Vol 10 (1) ◽  
pp. 66-76 ◽  
Author(s):  
Philippe Rochigneux ◽  
Lénaig Mescam-Mancini ◽  
Delphine Perrot ◽  
Erwan Bories ◽  
Laurence Moureau-Zabotto ◽  
...  

Gastrointestinal stromal tumours (GISTs) are mesenchymal tumours of the digestive tract, derived from Cajal interstitial cells. Bone metastases are very rare, and there is no consensus regarding their treatment. Here, we present the unusual case of a 66-year-old man with a gastric GIST with synchronous bone and liver metastases, fully documented at the pathological and molecular levels with a KIT exon 11 mutation. After 9 months of imatinib, the scanner showed a 33% partial response of target lesions. We also review the literature and describe the characteristics, treatment, and outcome of all cases previously reported.


Blood ◽  
1959 ◽  
Vol 14 (6) ◽  
pp. 748-758 ◽  
Author(s):  
PARVIZ LALEZARI ◽  
THEODORE H. SPAET

Abstract A panel of sera with leukoagglutinin activity was obtained from patients who had received multiple blood transfusions. Leukocytes of identical twins presented identical reaction patterns when tested against these sera, although no two unrelated subjects had identical leukocytes. None of the sera had identical reaction patterns with a panel of leukocytes from different subjects. Family studies failed to identify specific leukocyte antigens. It is concluded that there is a multiplicity of leukocyte antigens and that these are not related to erythrocyte antigens. The data suggest that febrile transfusion reactions in patients with leukoagglutinins may be avoided by use of bloods with compatible leukocytes.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1534-1534
Author(s):  
Kevin Cheng ◽  
Mehdi Nouraie ◽  
Xiaomei Niu ◽  
Evadne Moore-King ◽  
Margaret F. Fadojutimi-Akinsi ◽  
...  

Abstract Abstract 1534 Poster Board I-557 Background Low bone mass density affects more than 65% of adult sickle cell disease patients and correlates with lower hemoglobin and higher ferritin concentrations (1). Increased iron supply promotes osteoclast differentiation and bone resorption (2). Proinflammatory cytokines also promote bone resorption (3). Tartrate resistant acid phosphatase isoform 5b (TRACP-5b) is produced only by activated osteoclasts and therefore serves as a marker of bone resorption (4). Sickle cell disease is a condition of chronic inflammation and patients often suffer from transfusional iron overload as well. In this study we aimed to determine the predictors of bone resorption in patients with sickle cell disease by measuring circulating levels of TRACP-5b. Methods Fifty-nine adult sickle cell disease patients and 22 apparently healthy controls were recruited at Howard University Hospital. Patients were at steady state with no crisis, hospitalization or blood transfusion in the last 3 weeks. Clinical and laboratory information was collected at the time of recruitment and TRACP-5b was measured in non-fasting serum samples using an enzyme immuno assay kit (Quidel, San Diego, CA). Serum concentrations of inflammatory cytokines and growth factors were measured by Multiplex assay (Bio-Rad, Hercules, CA).. Results Sickle cell disease patients had elevated concentrations of TRACP-5b compared to controls (median values of 4.4 vs. 2.4 U/l, P < 0.0001). Among the patients, TRACP-5b concentrations correlated positively with number of blood transfusions (r = 0.19) and serum concentrations of alkaline phosphatase (r=0.46), endothelin-1 (r=0.39), interleukin-8 (r= 0.38), and interleukin-6 (r=0.25). TRACP-5b correlated negatively with RANTES (r = -0.42) and PDGF (r = -0.31). It did not correlate significantly with serum ferritin (r = -0.03), LDH (r = 0.13) or hemoglobin concentration (r = 0.11). Interestingly, TRACP-5b correlated positively with tricuspid regurgitation velocity, which reflects systolic pulmonary artery pressure (r = 0.30). Conclusion Sickle cell patients have elevated steady-state osteoclast activity as reflected in serum TRACP-5b concentrations. Multiple blood transfusions and inflammation are associated findings. Among patients, higher TRACP-5b concentrations are associated with lower concentrations of RANTES and PDGF-BB, factors that influence function of osteoblasts. Further studies are needed to investigate whether common pathways may be involved in osteoclast activation and pulmonary changes in sickle cell disease. Supported by grants number 2 R25 HL003679-08 and 1 R01 HL079912-02 and 1U54HL090508-01 from NHLBI, by Howard University GCRC grant no 2MOI RR10284-10 from NCRR, NIH, Bethesda, MD, and by the intramural research program of the National Institutes of Health. Disclosures Gordeuk: Biomarin: Research Funding; TRF Pharma: Research Funding; Merck: Research Funding; Novartis: Speakers Bureau.


Sign in / Sign up

Export Citation Format

Share Document